(Apr. 26) - Italian pharmaceutical group Recordati has announced the acquisition of the AIC, trademarks and other activities of six OTC medicines in Germany from the companies Cilag GmbH International and McNeil GmbH & Co. OHG. The products acquired are JHP-Rödler (mint oil indicated for digestive disorder, headache, cough and cold), Betadorm D (Diphenhydramine HCl indicated for sleep disorders), Rhinopront (pseudoephedrine+triprolidine indicated for rhinitis and head colds), Collomack Topical (salicylic acid solution, an anti- corn preparation), Tirgon (bisacodyl for constipation) and Xitix (vitamin C lozenges to treat vitamin C deficiency). Estimated 2012 sales for the six products are of around EUR 6 million euros. "The acquisition by our German subsidiary of these six well known brands represents an interesting opportunity to strengthen Recordati Pharma's OTC product portfolio", declared Giovanni Recordati, Chairman and CEO of the Recordati Group. "The OTC pharmaceutical segment in Germany is worth around EUR 4 billion and represents a share in units of 52% of the overall pharmaceutical market. Together with the existing OTC portfolio, which includes well known brands such as Mirfulan®, Osteoplus®, Dolobene®, Flosa® and Silibene®, the German subsidiary is now able to better exploit the OTC market potential by building a dedicated sales organization". (Red/Peg)

RECORDATI, AN INDUSTRIAL GIANT WITH 3200 EMPLOYEES
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange, with a total staff of over 3,200, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2011 was 762.0 million euros, operating income was 163.5 million euros and net income was 116.4 million euros.